An article published this year in “STEM CELLS INTERNATIONAL” using our CD29 FITC, by
our customers from Virotherapy and Gene therapy Group, ProCure Program,
Translational Research Laboratory, Instituto Catalan de Oncología IDIBELL,
Barcelona, Spain, in the analysis os Human menstrual blood-derived mesenchymal
stem cells as potential cell carriers for oncolytic adenovirus. Congrats and
Thanks.
Summary:
 |
| T cells (in gray) of the immune system surround the tumor cells (in green) thanks to the action of BiTE antibodies secreted by the oncolytic adenovirus. |
Antitumor efficacy of
systemically-administered oncolytic adenoviruses (OAdv) is limited due to diverse
factors such as liver sequestration, neutralizing interactions in blood,
elimination by the immune system, and physical barriers in tumors. It is
therefore of clinical relevance to improve OAdv bioavailability and tumor
delivery. Among the variety of tumor targeting strategies, the use of stem
cells and specifically bone marrow-derived mesenchymal stem cells (BM-MSCs) is of
particular interest due to their tumor tropism and immunomodulatory properties.
Nonetheless, the invasive methods
to obtain these cells, the low number of MSCs present in the bone marrow, and
their restricted in vitro expansion represent major obstacles for their use in
cancer treatments, pointing out the necessity to identify an alternative source
of MSCs. Here we have evaluated the use of menstrual blood-derived mesenchymal
stem cells (MenSCs) as cell carriers for regional delivery of an OAdv in the
tumor. Our results indicate that MenSCs can be isolated without invasive
methods, they have an increased proliferation rate compared to BM-MSCs, and
they can be efficiently infected with different serotype 5-based
capsid-modified adenoviruses, leading to viral replication and release. In
addition, our in vivo studies confirmed the tumor-homing properties of MenSCs
after regional administration.
Reference:
Product link:
No comments:
Post a Comment